



PC PRODUCTS INDIA LIMITED

(Formerly Known as Jayavant Industries Limited)

To,

Date: 23/08/2017

- 1) BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001
- 2) Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No C 62, Opp. Trident Hotel,
Bandra Kurla Complex, Bandra (E), Mumbai – 400 098
- 3) Ahmedabad Stock Exchange Limited
Kamdhenu Complex, Opp. Sahajanand College,
Panjara Pole, Ambawadi, Ahmedabad – 380 015

Sub: Outcome of Board Meeting under Regulation 30, 34 & 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Company's Letter dated 16/08/2017

Further to our above referred letter, this is to inform you that the Board of Directors of the Company at its meeting held today Wednesday, 23rd August, 2017 at 2.30 PM at Registered Office, have approved and taken on record the following:

1. Standalone Unaudited Financial Results for the **Quarter I ended 30th June, 2017** along with Limited Review Report issued by the Statutory Auditors of the Company in compliance with Indian Accounting Standards (Ind-AS).
2. The Company opts for submission of Audited Consolidated Financial Results on Yearly basis only as per Regulation 33 of SEBI (LODR) Regulations, 2015.
3. Investment in Innovision Life Sciences Private Limited.
4. Investment in M/s. Centre for Liver Research and Diagnostics (CLRD).
5. Issue of 8,00,000 Equity Shares and 37,50,000 Share Warrants convertible into Equity Shares on Preferential basis to Promoters and Non-Promoters.
6. Issue of 2,50,000 Employee Stock Options to Employees of Company & its Subsidiary's.
7. Increase in Authorized Share Capital of the Company from Rs. 13,00,00,000/- to Rs. 16,00,00,000 and subsequent Alteration of Memorandum of Association.

Regd. Off : 2-5-36/CLRD/1, Survey No. 36, Chintalmet X Roads, Upperpally, Attapur, Rajendra Nagar Mandal, Hyderabad – 500 048, Telangana, India

CIN No : L85110TG1996PLC099198

Contact No : 040 – 2970 3333, +91 – 90300 57370

E-Mail : pcproductsindia@gmail.com

Website : pcproductslimited.com



8. Entering into the following areas of Health Care Sector by the Company (as per the Main Objects of the Company mentioned in MOA) –
- New Drug Discovery including New Molecular Entity (NME – Pro Drug)
 - Clinical Research Organization (CRO) related activities
 - Academic Services like Courses / Lectures / Seminars on Biotechnology, Pharma, Stem Cell Research and therapy, Clinical Research and animal studies etc.
 - Nutraceuticals product development
 - Trading, exporting and importing of medicinal drugs, chemicals, re-agents etc.

9. The following agreements have been entered by the Company with its related parties:

- a) Collaborative Agreement with Centre for Liver Research and Diagnostics (CLRD) as per the acceptable prudent norms to use the facilities including equipment's to enter into businesses:
- Pharmacy
 - Stem Cell – Lab, Research & Therapy
 - R&D in Bio technology

The Promoters of the Company are also holding major stake and control over the management of Centre for Liver Research and Diagnostics (CLRD); thus being related parties to the transaction and further, the Company is investing in CLRD to make it as part of group entity.

- b) Master Collaborative Agreement with Krisani Bio Sciences Private Limited (KBSPL), a Subsidiary of PC Products India Limited to further develop the Molecule "KB-HD-01".
- c) The Company's Corporate Office at #Villa No. 11, Phase 1, Vasudeva Bloomfield Elation, Near Delhi Public School, Khajaguda, Nanakramguda, Hyderabad – 500008, Telangana and Sample Collection Center relating to Diagnostics at #6-3-354/13, Flat No. B2, Suryateja Apartements, Hindi Nagar, Punjagutta, Hyderabad – 500034, Telangana.

The Company has taken the above properties on lease and the rent payable shall be lower than the market rental value. The properties belong to the Promoter Director & Executive Chairman of the Company, Mr. K. Krishnam Raju and his relatives; being related parties to the transaction.

- d) Payment of Fees in professional capacity to the Promoter Directors of the Company (being related parties) for rendering services in professional capacity at ORIGIN HOSPITALS and other divisions.

10. Change of Name of the Company from PC PRODUCTS INDIA LIMITED TO DR HABEEBULLAH LIFE SCIENCES LIMITED.



11. Notice of 21st Annual General Meeting along with Annual Report for the Financial Year 2016-17 scheduled to be held on Wednesday, the 27th September, 2017 at 10.30 AM at the Registered Office of the Company at 2-5-36/CLRD/1, Survey No. 36, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad – 500 048, Telangana, India.
12. Register of Members and Share Transfer Books of the Company will remain closed from Thursday, 21st September, 2017 to Wednesday, 27th September, 2017 (both days inclusive) for the purpose of convening 21st Annual General Meeting of the Company.
13. The Board of Directors of the Company has appointed Mr. S. Sarveswar Reddy, Company Secretary in Whole-time Practice, M/s. S.S. Reddy & Associates to act as Scrutinizer for the ensuing 21st Annual General Meeting.
14. The Board has decided to commence E-Voting from Sunday, 24th September, 2017 (09:00 hrs) and will end on Tuesday, 26th September, 2017 (17:00 hrs).

Note: Transactions mentioned in S.No. 5 to 10 are considered for approval of Shareholders in the ensuing 21st Annual General Meeting.

The meeting commenced at 2.30 PM and concluded at 5.00 PM.

Request you take the same on records.

Thanking you.

For PC Products India Limited



K. Krishnam Raju
Executive Chairman (DIN 00874650)

Encl: as above

DISCLOSURE OF PARTICULARS RELATING TO PREFERENTIAL ISSUE OF EQUITY SHARES

PARTICULARS	DESCRIPTION
Type of Securities proposed to be issued	EQUITY SHARES TO NON-PROMOTERS
Total No. of Securities and Amount for which Securities will be issued	8,00,000 Equity Shares Issue Price – Rs. 20.00/- Face Value – Rs. 10.00/- Premium – Rs. 10.00/-
Details of Investors (Name and No. of Equity Shares)	1. Mr. Kalidhindi, Janakirama Raju – NRI (4,00,000 Equity Shares) 2. Ms. Kalidhindi, Rejeswari Harika – US Citizen, Indian Origin (4,00,000 Equity Shares)

DISCLOSURE OF PARTICULARS RELATING TO PREFERENTIAL ISSUE OF SHARE WARRANTS

PARTICULARS	DESCRIPTION
Type of Securities proposed to be issued	CONVERTIBLE SHARE WARRANTS INTO EQUITY SHARES
Total No. of Securities and Amount for which Securities will be issued	10,00,000 Share Warrants to Promoters 27,50,000 Share warrants to Non Promoters Issue Price – Rs. 20.00/- Face Value – Rs. 10.00/- Premium – Rs. 10.00/-
Details of Investors (Name and No. of Warrants)	Promoters: 1. Dr. Mohammed Aejaaz Habeeb – 5,00,000 2. Dr. Syed Ameer Basha Paspala – 5,00,000 Non-Promoters/Indian Public: 1. Mr. M. Sarvothama Reddy – 6,00,000 2. Ms. M. Neela Reddy – 6,25,000 3. Mr. M. Srinivas Chaitanya – 3,00,000 4. Ms. M. Prabha Sameera – 6,00,000 5. Ms. Nikita Korupolu – 3,00,000 6. Mr. Ravi Mandava – 1,00,000 7. Mr. Mohan Reddy CV – 75,000 8. Ms. C. Suguna – 50,000 9. Ms. Anita Lakkadi – 1,00,000



DISCLOSURE OF PARTICULARS RELATING TO THE ISSUE OF ESOPs

PARTICULARS	DESCRIPTION
Date of institution of the scheme of the scheme	Wednesday, 23 rd August, 2017
Validity period of the scheme	The Scheme shall continue to be in force until (i) its termination by the Board or (ii) the date on which all the options available for issuance under the Plan have been issued and exercised
Date of Members approving the scheme/amending the scheme/approving grants under regulation 6(3) of the SEBI (Share Based Employee Benefits) Regulations, 2014	Resolution proposed in ensuing 21 st Annual General Meeting to be held on Friday, 27 th September, 2017
Kind of benefit granted under the scheme	Options to acquire Equity Shares
Identity of classes of persons eligible under the scheme	Employees of Company and its Subsidiary' s
Total number of Equity Shares reserved under the scheme, as applicable	2,50,000 Equity Shares for 2,50,000 Options (Ratio 1:1)
Exercise price or pricing formula	As decided by NRC, But not below par value and not exceeding market price as on date of the grant

* The Number of Equity Shares to be allotted may vary based on Foreign Exchange Conversion Rate.

** The Issue is subject to statutory approvals, as applicable.

Handwritten signature



PC PRODUCTS INDIA LIMITED

(Formerly known as Jayavant Industries Limited)

Regd. Office: 2-5-36/CLRD/1, Sy No. 36, Chintalmet X Roads, Upperpally, Attapur, Rajendra Nagar Mandal,
Hyderabad – 500 048, Telangana, India

Contact No. 040-2970 3333, +91 90300 57370

E-mail id: pcproductsindia@gmail.com

CIN No : L85110TG1996PLC099198

Website : pcproductslimited.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER I ENDED 30TH JUNE, 2017

		Rs. in Lacs	
		Quarter Ended	
		30-06-2017	30-06-2016
		UnAudited	UnAudited
I	Income from Operations		
	Net Sales / Income from Operations (Net of Excise Duty)	2.55	31.27
	Other Operating Income	-	1.18
	Total Income from Operations (Net)	2.55	32.45
II	Expenses		
	Cost of Material Consumed		
	Purchase of Stock-in-trade	-	30.65
	Changes in inventories of finished goods, Work in progress and Stock in trade	-	-
	Employee Costs	22.19	1.65
	Employee benefits expense	-	-
	Finance Cost	-	-
	Depreciation and Amortisation expense	-	-
	Other Expense	11.17	4.37
	Total Expenses	33.36	36.67
		-30.81	-4.22
III	Profit/ (Loss) from from Operations before Other Income, Finance Costs and Exceptional Items (I-II)		
IV	Other Income	-	-
V	Profit/ (Loss) from Ordinary activities before finance costs and exceptional items (III+IV)	-30.81	-4.22
VI	Finance Cost	-	-
VII	Profit/ (Loss) from Ordinary activities after finance costs but before exceptional items (V+VI)	-30.81	-4.22
VIII	Exceptional Items	-	-
IX		-30.81	-4.22
	Profit/ (Loss) from ordinary activities before tax (VII+VIII)		
X	Tax Expense	-	-
XI	Profit/ (Loss) from ordinary activities after tax (IX+X)	-30.81	-4.22
XII	Extraordinary Items (net of tax Rs. expense ----- lacs)	-	-
XIII	Net Profit/ (Loss) for the period (XI+XII)	-30.81	-4.22
XIV	Share of Profit / (Loss) of Associates	Not Applicable as Consolidation on Yearly basis only	
XV	Minority Interest		
XVI	Net Profit/ (Loss) after taxes, minority interest and share of profit / (loss) of associates (XIII+XIV+XV)	-30.81	-4.22
		1025.87	538.81
XVII	Paid Up Equity Share Capital (Face Value Rs. 10/- per share)		
XVIII	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-190.07	-158.1
XIX	Earnings Per Share (EPS) (before extraordinary items) (Face Value Rs. 10/- each) (not annualised)		
	Basic	-0.30	-0.08
	Diluted	-0.30	-0.08
XX	Earnings Per Share (EPS) (after extraordinary items) (Face Value Rs. 10/- each) (not annualised)		
	Basic	-0.30	-0.08
	Diluted	-0.30	-0.08



Notes:

- 1 Beginning April, 2017; the Company has for the first time adopted the Indian Accounting Standards (Ind AS) with a transition date of April, 2016 and accordingly these financial statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder.
- 2 The format for the Unaudited quarterly results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.1(iii) has been availed. Hence, Figures of corresponding previous quarter and previous year have not been provided.
- 3 There is a possibility that these quarterly financial results may require adjustment before compiling the final Ind AS financial statements as of and for the year ending March 31, 2018 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from retrospective application of certain Ind AS as permitted under Ind AS 101.
- 4 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 5 The Company has only one reportable segment i.e., Bio-Pharma Sector. Hence, the separate disclosure on Segment information is not required.
- 6 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Wednesday, 23rd August, 2017.
- 7 The Standalone Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.
- 8 The results are also available on the website of the Company www.pcproductslimited.com
- 9 Reconciliation between Financial Results previously reported (referred to as PREVIOUS GAAP) and Ind AS for the Quarter ended 30th June, 2016 (As per paragraph 32 of Ind AS 101)

Particulars	Quarter Ended 30th June, 2016 (Rs. In Lacs)
Net Profit as per previous GAAP	-4.22
Increase in profit due to:	
Fair Value Impact for financial instrument	NIL
Net Profit after Ind AS (After Tax)	-4.22
Other Comprehensive Income	NIL
Total Comprehensive Income under Ind AS	-4.22

- 10 As per Reg 33 of SEBI (LODR) Regulations, 2015, the Company has opted to declare and publish Quarterly Unaudited Financial Results and to declare, publish the Consolidated Results on Yearly basis only.

For PC Products India Limited



[Handwritten Signature]

Place : Hyderabad
Date : 23rd August, 2017

K. Krishnam Raju
Executive Chairman (DIN 00874650)



N. M. KHATAVKAR & CO.
CHARTERED ACCOUNTANTS

Cell : 94488 37388
Tele / Fax : 0836 2258841
Email : nandrajkhataavkar@yahoo.com
nmk1365@gmail.com

Limited Review Report

Review Report to Board of Directors
PC Products India Limited, Hyderabad, Telangana.

We have reviewed the accompanying Statement of **Standalone Unaudited Financial Results** of **PC Products India Limited** (Formerly Known as Jayavant Industries Limited) for the **Period/Quarter I Ended 30th June 2017**. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Standalone Financial Results prepared in accordance with applicable Indian Accounting Standards prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016; including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hubli
Date: 23/08/2017

Chartered Accountants

For N.M.Khataavkar & Co.



For N. M. Khataavkar & Co.
Chartered Accountant

(Khataavkar N. M.)
Proprietor

Membership Number : 206569
Firm Regn No. 007939 S

N.M.Khataavkar Proprietor
Membership No. 206569
Firm Regd No. 007939S

